brand logo

Am Fam Physician. 2023;107(5):550-551

Author disclosure: No relevant financial relationships.

The Lumipulse G β-Amyloid Ratio assay is a cerebrospinal fluid (CSF) test used to assist in the diagnosis of Alzheimer disease in patients 55 years or older with cognitive impairment. In May 2022, the U.S. Food and Drug Administration authorized the test for marketing.1 Lumipulse G is an automated system for bead-based immunoassays that measure biomarkers for Alzheimer disease, including amyloid β (Aβ)1-42, total tau, phosphorylated tau, and the Aβ1-42: Aβ1-40 ratio.2 These proteins can accumulate to form amyloid plaques, which may be associated with Alzheimer disease.

Amyloid plaque formation decreases the Aβ1-42: Aβ1-40 ratio; thus, a low ratio supports the diagnosis of Alzheimer disease.3 In three independent cohorts of older adults with cognitive symptoms in Canada, Italy, and the Czech Republic, a cutoff value of 0.072 was established based on correlation with amyloid plaques detected on positron emission tomography (PET) scans and other immunoassay tests.46

Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

This series is coordinated by Natasha Pyzocha, DO, contributing editor.

A collection of Diagnostic Tests published in AFP is available at

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.